Form 4: Halozyme Therapeutics Director Matthew L. Posard Reports Stock and Option Grants

Director Matthew L. Posard reports the acquisition of restricted stock units and stock options in Halozyme Therapeutics, Inc.

Summary

• On April 25, 2024, Matthew L. Posard, a director of Halozyme Therapeutics, Inc., reported the acquisition of 6,501 shares of common stock through a restricted stock unit (RSU) grant and an option to purchase 8,804 shares of common stock.
• The RSU grant vests on the earlier of April 25, 2025, or the date of the next annual meeting of stockholders.
• The stock option grant, with an exercise price of $38.46, also vests on the earlier of April 25, 2025, or the date of the next annual meeting of stockholders and expires on April 25, 2034.
• Following these transactions, Posard directly owns 119,755 shares of Halozyme Therapeutics common stock and options to purchase 8,804 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard director compensation practices, aligning interests with shareholders.

Positives

• The grants of RSUs and stock options to a director align their interests with those of the shareholders.
• The vesting schedule encourages continued service as a director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the grants.

Industry Context

This type of equity compensation is standard practice for directors of publicly traded companies to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Director compensation packages typically include a mix of cash, stock options, and restricted stock units.
• The vesting schedules are generally aligned with the company's annual meeting cycle or a specific term of service.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation for their board members.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates